Ken Griffin Axonics, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$66.47 - $69.65 $206,057 - $215,915	-3,100 Reduced 36.47%	5,400 $363,000
Q1 2024 May 15, 2024	SELL	$56.67 - $69.36 $85,005 - $104,040	-1,500 Reduced 15.0%	8,500 $586,000
Q4 2023 Feb 14, 2024	SELL	$49.38 - $63.75 $1.03 Million - $1.33 Million	-20,800 Reduced 67.53%	10,000 $622,000
Q3 2023 Nov 14, 2023	BUY	$48.64 - $62.51 $525,312 - $675,108	10,800 Added 54.0%	30,800 $1.73 Million
Q2 2023 Aug 14, 2023	BUY	$47.99 - $60.21 $585,478 - $734,562	12,200 Added 156.41%	20,000 $1.01 Million
Q1 2023 May 15, 2023	SELL	$52.6 - $67.34 $247,220 - $316,498	-4,700 Reduced 37.6%	7,800 $425,000
Q4 2022 Feb 14, 2023	BUY	$59.56 - $76.6 $440,744 - $566,840	7,400 Added 145.1%	12,500 $781,000
Q3 2022 Nov 14, 2022	SELL	$57.96 - $78.12 $17,388 - $23,436	-300 Reduced 5.56%	5,100 $359,000

241

42.8M

73.7K

230K

Ticker AXNX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 49,123,600
Market Cap $3.38B
Description
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.